Cumberland Pharmaceuticals (CPIX)
(Delayed Data from NSDQ)
$1.31 USD
+0.03 (2.34%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.35 +0.04 (3.05%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.31 USD
+0.03 (2.34%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.35 +0.04 (3.05%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
New Strong Sell Stocks for December 4th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Cumberland Pharmaceuticals (CPIX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Cumberland Pharmaceuticals (CPIX) closed at $5.56 in the latest trading session, marking a -0.18% move from the prior day.
What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings?
by Zacks Equity Research
Cumberland Pharmaceuticals' (CPIX) third-quarter results are expected to reflect solid sales growth.
Cumberland Pharmaceuticals (CPIX) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cumberland Pharmaceuticals (CPIX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cumberland Pharmaceuticals (CPIX) closed at $5.34 in the latest trading session, marking a +0.75% move from the prior day.
Cumberland Pharmaceuticals (CPIX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cumberland Pharmaceuticals (CPIX) closed at $5.30 in the latest trading session, marking a -1.6% move from the prior day.
Cumberland Pharmaceuticals (CPIX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Cumberland Pharmaceuticals (CPIX) closed at $5.44 in the latest trading session, marking a -1.72% move from the prior day.
Cumberland Pharmaceuticals (CPIX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cumberland Pharmaceuticals (CPIX) closed at $5.67, marking a +1.61% move from the previous day.
Cumberland Pharmaceuticals (CPIX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cumberland Pharmaceuticals (CPIX) closed the most recent trading day at $5.70, moving -1.38% from the previous trading session.
New Strong Buy Stocks for September 26th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
New Strong Buy Stocks for September 19th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Cumberland Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Cumberland Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Cumberland (CPIX) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for September 12th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Theravance Announces Positive Early Data on JAK Inhibitor
by Zacks Equity Research
Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.
New Strong Buy Stocks for September 9th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Here is Why Growth Investors Should Buy Cumberland (CPIX) Now
by Zacks Equity Research
Cumberland (CPIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
New Strong Buy Stocks for September 5th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Here is Why Growth Investors Should Buy Cumberland (CPIX) Now
by Zacks Equity Research
Cumberland (CPIX) could produce exceptional returns because of its solid growth attributes.
Cumberland Pharmaceuticals (CPIX) Q2 Earnings Beat Estimates
by Zacks Equity Research
Cumberland (CPIX) delivered earnings and revenue surprises of 42.86% and -8.01%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Cumberland Pharmaceuticals (CPIX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dova Pharmaceuticals (DOVA) in Focus: Stock Moves 9.1% Higher
by Zacks Equity Research
Dova Pharmaceuticals (DOVA) shares rose more than 9% in the last trading session, amid huge volumes.
Acer Shares Down on FDA's CRL for Genetic Disorder Treatment
by Zacks Equity Research
Acer Therapeutics Inc. (ACER) receives a Complete Response Letter from the FDA regarding its new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.
Cumberland Pharmaceuticals (CPIX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Cumberland Pharmaceuticals (CPIX) closed at $6.35, marking a +0.79% move from the previous day.
Why Taro Pharmaceutical (TARO) Could Be Positioned for a Slump
by Zacks Equity Research
Taro Pharmaceutical (TARO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.